News US regulators reject Akcea and Ionis rare disease drug The US Food and Drug Administration (FDA) rejected Akcea and Ionis’ application for the use of Waylivra in treatment of familial chylomicronemia syndrome (FCS) despite earlier support of ex
News AZ grabs licence as Ionis NASH drug heads to the clinic Could antisense drug be a fatty liver disease blockbuster?
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Roche takes on development of potential Huntington’s breakth... Ionis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in treating Huntington’s disease.
News Alnylam soars after drug success, paving way for RNAi era Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends